Key takeaways
- GLP-1 drugs have crossed from clinical into commercial territory: 18% of US adults are now using them, per-household grocery spend is down 5.5%, and JPMorgan estimates $30–$55 billion in annual food and beverage revenue is at risk by 2030
- The impact goes well beyond grocery. Apparel spend among users is up 9.9%, protein supplement consumption is surging, and foodservice is splitting sharply between QSR and full-service formats
- The US is the live experiment; the UK and GCC are already following, while 85% of current GLP-1 users say brands have not responded meaningfully yet
Τhe grocery store was designed for a consumer who ate more. And that is a fact.
The modern grocery store is an archive of assumptions. Its layout — fresh perimeter, packed center aisle, checkout loaded with impulse items — was built around a consumer who wanted volume, frequency and convenience at scale. Those assumptions held for decades. They are now being tested by something the industry did not anticipate: a class of drugs that pharmacologically suppresses the behaviors the store was built to monetize.
Glucagon-like peptide-1 receptor agonists, a.k.a. GLP-1 drugs, reduce appetite, slow digestion and alter how users relate to food. The most recognized are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Originally approved for diabetes management, both are now widely used for weight loss. And their reach is expanding fast. As of 2026, the GLP-1 impact on retail is measurable, category by category, in purchase data.
What the US data shows
The United States is the most advanced market for GLP-1 adoption and the only one where retail impact data exists at sufficient scale to analyze rigorously.
According to FTI Consulting’s spring 2026 survey of 1,007 US adults, 18% of Americans are now using GLP-1 medications, up from 14% in 2025. PwC, drawing on Numerator panel data, places the figure at 21% of US households including at least one current user — up from 9% in January 2025 alone. The 35-to-54 group leads adoption at 23%, and 54% of current users have been on the drugs for more than a year.
The result? The grocery basket is restructuring, not merely shrinking. PwC’s 2026 GLP-1 Usage and Attitudes Survey found that 61% of current users are buying fewer sweet treats and 56% fewer salty snacks, while 44% are buying more fresh produce and 35% more packaged protein. Frozen foods have taken the single largest packaged food hit: a three-point drop in dollar spend within the first year of use. In other related news, non-alcoholic sugary drinks are contracting. Functional beverages and water filtration products are growing.
Per-household grocery spend is down 5.5%. Cornell University research puts the reduction per grocery trip at between 5.3% and 8%. JPMorgan estimates that GLP-1 adoption could eliminate $30 to $55 billion in annual food and beverage revenue by 2030, with users consuming 21% fewer calories and spending 31% less on groceries on average. Big Chalk Analytics calculates that $6.5 billion in US grocery sales has already been lost to GLP-1-driven reduced snacking behavior.
One dynamic the headline numbers obscure: GLP-1 users are buying less but spending more per item. FTI Consulting’s data shows that while volumes of chips, baked goods, and soft drinks have fallen sharply, overall dollar spend on those same categories has held, a clear premiumization effect. Fewer purchases, higher unit price. Retailers tracking basket value rather than basket size will find more nuance in this market than the volume numbers suggest.
It’s not only a grocery story
Weight loss drugs and food retail dominate the analysis, but the spending shifts do not stop at the supermarket door.
PwC’s survey found apparel spend up 9.9% among GLP-1 users after six to eight months on the medication, with nearly three quarters reporting a meaningful change in clothing size. Bodies are changing faster than wardrobes and the purchase data proves it: women’s jeans up 66%, swimwear at 31%, dresses at 22%, and jewelry at 36.4%.
The supplement category is responding to the same underlying pressure. Approximately 80% of GLP-1 users consume performance and health nutrition products, compared with roughly 67% of the general population, according to FTI Consulting. Protein shakes, bars, and snacks are seeing mid-teens consumption increases. Protein is the priority. Between 20% and 40% of weight lost on GLP-1 medications comes from lean muscle mass, which creates genuine clinical demand for protein supplementation.
Foodservice is splitting in two. QSR wallet share has fallen while full-service restaurant share has risen in high-adoption areas. The 35-to-54 olds — the group leading GLP-1 adoption — is eating out more often but spending more per occasion, choosing full-service over convenience. Volume is down. The bill per visit is up.
Is the GLP-1 impact on retail heading global?
The US is the leading indicator. Adoption is highest there, the retail impact data most rigorous, and the industry response — however incomplete — most developed. It will not remain the only one.
In the UK, the Health Foundation estimates 2.4 million people are currently accessing GLP-1 medications, with private prescriptions outpacing NHS supply by a considerable margin. A January 2026 survey by The Food Foundation found that 7% of the British population have already used GLP-1 drugs, with a further 8% considering them. In response, supermarkets have launched GLP-1-friendly product lines — portion-controlled, high-protein, high in fiber — making the UK the only market outside the US where category-level retail response is visible at scale.
The GCC presents a different trajectory. Obesity rates in the region exceed 40%, and a 2026 study from King Faisal University found that 72.6% of Saudi survey participants had already heard of GLP-1 receptor agonists. In fact, Saudi Arabia holds the largest market share in the MEA GLP-1 market and is projected to register the highest regional growth rate through 2033. Regional foodservice chains are beginning to introduce compatible menu items. The branded packaged food category in the Kingdom has not yet produced a dedicated GLP-1 product line. One thing is sure: that gap will not stay open long.
Mainland Europe sits further back, with roughly 2% adoption across the EU and UK combined, but the direction is consistent. As European consumer discretionary spending continues to face pressure across categories, GLP-1-driven demand shifts will compound an already difficult environment for grocery and food retail operators.
What a retail response looks like
PwC’s data is clear: 85% of current GLP-1 users say companies have not responded meaningfully, while 47% have not seen brands do anything at all.
Some have moved early, expanding fresh perimeter space, repositioning checkout zones toward protein formats and functional hydration, co-merchandising wellness categories adjacent to pharmacy counters. FTI Consulting’s framework for grocery retail trends points to three priorities: honest portfolio assessment to identify where volume pressure is structural versus where premium repositioning is viable; R&D reoriented toward muscle preservation, digestive support, and high-protein formulation; and communications built around what this consumer actually needs, not what the previous decade assumed they wanted.
The 35-to-54 age group is the commercial anchor. Eating out more, spending more per occasion, buying more apparel, building supplement routines.
The grocery store built for a consumer who ate more is still standing. It just has fewer customers who still shop that way. The Q1 2026 grocery earnings already showed the first cracks, and the GLP-1 impact on retail has only accelerated since.
